Adoption of the Resolution on Strengthening Diagnostics capacity at the 76th World Health Assembly

CHMP recommends Ronapreve for the treatment of hospitalised COVID-19 patients

Roche statement on FDA Oncologic Drug Advisory meeting on 9 March 2023

Roche provides update on Tecentriq US indication for previously untreated metastatic bladder cancer

Roche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actions

Roche and the World Health Organization partner to improve access to Actemra®/RoActemra® (tocilizumab) for COVID-19 in low- and middle-income countries

Additional studies confirm Roche SARS-CoV-2 Rapid Antigen Tests’ sensitivity against Omicron variant

Viruses mutate over time, and SARS-CoV-2 is no exception

How Roche tests and medicines continue to play a key role as pandemic evolves

Ronapreve does not retain neutralising activity against the Omicron variant

Roche statement on termination of partnership with Atea Pharmaceuticals to develop AT-527

Roche statement on follow-up analysis of Ronapreve phase III prevention trial

WHO recommends the use of Ronapreve™ (casirivimab and imdevimab) in COVID-19 patients

Roche statement on global supply constraints of Actemra/RoActemra

World Health Organization issues new treatment recommendations for the clinical management of COVID-19

Roche statement on the preliminary phase III data from UK University of Oxford-led RECOVERY trial for casirivimab and imdevimab

Roche statement on FDA Oncologic Drug Advisory Meetings on 27–29 April 2021

Roche statement on the European Medicines Agency (EMA) commencement of review for Regeneron’s antibody cocktail (casirivimab and imdevimab)

Roche statement on casirivimab and imdevimab data in preventing COVID-19 infections within households

Roche statement on casirivimab and imdevimab data in hospitalised patients

Roche statement on new variants of SARS-CoV-2 found in the UK

Roche statement on FDA acceptance of casirivimab and imdevimab (REGNCOV2) EUA in the US

Changes recommended to ongoing REGN-COV2 study in hospitalized patients by Independent Data Monitoring Committee

Roche statement on REGN-COV2 data in non-hospitalised patients

Roche statement on REGN-COV2 US Emergency Use Authorization Request

Roche statement regarding UK diagnostics products supply issue

Roche statement on REGN-COV2 virology phase II data

Roche to divest legacy Genentech facility in Vacaville, California, as part of long-term strategy to evolve manufacturing capabilities